These findings indicate that CREB3L1 exhibits great potential as a predictive biomarker for anti-cancer drugs sensitivity and a novel therapeutic target in human cancers, and dynamic monitoring of CREB3L1 expression may be a valuable approach to effectively evaluate therapeutic responses of cancer patients, thus helping choose the most suitable treatment strategy for the individual patient. This evidence concerns the gene CREB3L1 and cancer.